The clinical efficacy of recombinant human thrombopoietin for the treatment of post-chemotherapy throm- bocytopenia of adult patients with acute myeloid leukemia
10.3969/j.issn.1006-5725.2017.16.026
- VernacularTitle:重组人血小板生成素治疗成人急性髓系白血病化疗后血小板减少的临床疗效
- Author:
Ting JIN
- Keywords:
recombinant human thrombopoietin;
acute myeloid leukemia;
thrombocytopenia;
adverse reactions
- From:
The Journal of Practical Medicine
2017;33(16):2711-2713
- CountryChina
- Language:Chinese
-
Abstract:
Objective To study the effect of recombinant human thrombopoietin(rh TPO)for the treatment of post-chemotherapy thrombocytopenia in adult patients with acute myeloid leukemia(AML). Methods A total of 60 newly diagnesed AML patients ,law-and Intermediate-Rist with post-chemotherapy thrombocytopenia were randomly divided into experimental group (30 cases,rh TPO treatment)and control group(30 cases,no rhTPO treatment). Comparisons were made on the blood platelet recovery degree,the days of the blood platelet counting less than 20 × 109/L,the recovery days of the blood platelet counting more than 50 × 109/L,and incidence of adverse reac-tions of experimental group. Results After treatment,blood platelet recovery level between the experimental group and the control group has no difference(P>0.05). The days of the blood platelet counting less than 20 × 109/L and the recovery days of the blood platelet counting more than 50 × 109/L of experimental group were less than the control group separately(P < 0.05). The experimental group had low incidence of adverse reactions(6.7%). Conclusion rhTPO can not significantly increase the level of platelet recovery of AML patients after chemotherapy ,but can obvi-ously shorten the time of platelet recovery without obvious adverse reactions. The specific time needs further studied.
